These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38449356)

  • 21. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
    Yassine D; Brown EN; Putney D; Fasoranti O
    J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heavy menstrual bleeding in women on oral anticoagulants.
    Samuelson Bannow BT; Chi V; Sochacki P; McCarty OJT; Baldwin MK; Edelman AB
    Thromb Res; 2021 Jan; 197():114-119. PubMed ID: 33212377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
    Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
    Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
    Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R
    J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    DeCamillo D; Haymart B; Barnes GD
    J Thromb Thrombolysis; 2022 Apr; 53(3):601-606. PubMed ID: 34559367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
    Chen J; Bi G; Wu F; Qin X
    Pediatr Res; 2023 May; 93(6):1491-1498. PubMed ID: 36071237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
    Pasciolla S; Zizza LF; Le T; Wright K
    Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
    Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
    Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
    Hedvat J; Howlett C; McCloskey J; Patel R
    J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
    Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
    Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
    Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
    Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
    Nemola G; Russi A; Cozzani G; Leo G; Vetrugno L; Sparasci FM; Parlati AL; Della Bella P; Montorfano M; Tresoldi M; Salerno A; Cera M; Mattiello P; Comi G; Maisano F; Zangrillo A; Gaspardone C; Melillo F; Margonato A; Godino C;
    Am J Cardiol; 2023 Nov; 206():125-131. PubMed ID: 37703678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
    Brodie MM; Newman JC; Smith T; Rockey DC
    Am J Med; 2018 May; 131(5):573.e9-573.e15. PubMed ID: 29175237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
    Gedikli Ö; Altay S; Ünlü S; Çakmak HA; Aşkın L; Yanık A; Beşli F; Sinan ÜY; Canpolat U; Şahin M; Pehlivanoğlu S
    Anatol J Cardiol; 2021 Mar; 25(3):196-204. PubMed ID: 33690135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants.
    Sengupta N; Marshall AL; Jones BA; Ham S; Tapper EB
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1893-1900.e2. PubMed ID: 29775794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
    Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
    Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.